Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
British Journal of Cancer|April 1, 2016
Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR studyW Janni, N Harbeck, B Rack, et al.
Breast Cancer Research and Treatment|May 13, 2015
Obesity as an independent risk factor for decreased survival in node-positive high-risk breast cancerChristoph Scholz, U Andergassen, P Hepp, et al.
Journal of Cancer Research and Clinical Oncology|February 25, 2015
Circulating tumor cells versus objective response assessment predicting survival in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapyM Thalgott, M M Heck, M Eiber, et al.
Biomed Research International|May 7, 2014
Evaluation of two different analytical methods for circulating tumor cell detection in peripheral blood of patients with primary breast cancerB A S Jaeger, J Jueckstock, U Andergassen, et al.
Geburtshilfe Und Frauenheilkunde|May 31, 2016
Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A TrialL Schröder, B Rack, H Sommer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 13, 2018
Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trialM Ignatiadis, S Litière, F Rothe, et al.
Breast (Edinburgh, Scotland)|July 22, 2017
Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A studyElisabeth Trapp, J Steidl, B Rack, et al.
ESMO Open|November 28, 2021
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study programV Müller, M Banys-Paluchowski, T W P Friedl, et al.
ESMO Open|March 22, 2025
Detection of minimal residual disease and prediction of recurrence in breast cancer using a plasma-only circulating tumor DNA assayW Janni, B Rack, T W P Friedl, et al.
British Journal of Cancer|August 16, 2012
Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trialI Witzel, S Loibl, G von Minckwitz, et al.
Pageof 4